Abstract
Neuronal nitric oxide synthase (nNOS) produces the key signalling mediator nitric oxide, (NO). This gaseous, free radical molecule modulates a vast array of biological processes, from vascular pressure to immune responses and neurological signalling cascades. Overproduction of NO has been implicated in conditions including Alzheimer’s disease, Parkinson’s disease and schizophrenia. Inhibition of nNOS therefore offers a potential therapeutic approach for treatment of these conditions. This endeavour is made more complex by the fact that there are two other isoforms of nitric oxide synthase (NOS), endothelial NOS (eNOS) and inducible NOS (iNOS). The selectivity of nNOS inhibitors is therefore a key concern for therapeutic development. This review explores recent advances in the field of selective nNOS inhibition. A particular focus is placed on computational approaches towards the rational design of selective nNOS ligands with improved pharmacokinetic properties. These ligands have been targeted at four key binding sites of the nNOS enzyme - the tetrahydrobiopterin, calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH) and arginine binding sites. The binding sites, and the compounds used to inhibit them, will be discussed in turn, along with the computational methods which have been employed in the field of nNOS inhibition.
Keywords: Binding pockets, in silico, neuronal nitric oxide synthase (nNOS), selective inhibition.
Current Medicinal Chemistry
Title:Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations
Volume: 22 Issue: 21
Author(s): Adam M. Curtin, Gemma K. Kinsella and John C. Stephens
Affiliation:
Keywords: Binding pockets, in silico, neuronal nitric oxide synthase (nNOS), selective inhibition.
Abstract: Neuronal nitric oxide synthase (nNOS) produces the key signalling mediator nitric oxide, (NO). This gaseous, free radical molecule modulates a vast array of biological processes, from vascular pressure to immune responses and neurological signalling cascades. Overproduction of NO has been implicated in conditions including Alzheimer’s disease, Parkinson’s disease and schizophrenia. Inhibition of nNOS therefore offers a potential therapeutic approach for treatment of these conditions. This endeavour is made more complex by the fact that there are two other isoforms of nitric oxide synthase (NOS), endothelial NOS (eNOS) and inducible NOS (iNOS). The selectivity of nNOS inhibitors is therefore a key concern for therapeutic development. This review explores recent advances in the field of selective nNOS inhibition. A particular focus is placed on computational approaches towards the rational design of selective nNOS ligands with improved pharmacokinetic properties. These ligands have been targeted at four key binding sites of the nNOS enzyme - the tetrahydrobiopterin, calmodulin, nicotinamide adenine dinucleotide phosphate (NADPH) and arginine binding sites. The binding sites, and the compounds used to inhibit them, will be discussed in turn, along with the computational methods which have been employed in the field of nNOS inhibition.
Export Options
About this article
Cite this article as:
Curtin M. Adam, Kinsella K. Gemma and Stephens C. John, Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations, Current Medicinal Chemistry 2015; 22 (21) . https://dx.doi.org/10.2174/0929867322666150429112600
DOI https://dx.doi.org/10.2174/0929867322666150429112600 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Human Immunodeficiency Virus (HIV) and Stroke: Targets for Intervention
Infectious Disorders - Drug Targets Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets The Use of Sensory Nerve Stimulation and Compression Bandaging to Improve Sensory Nerve Function and Healing of Chronic Venous Leg Ulcers
Current Aging Science Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis: An Uncommon Yet Important Complication
Current Rheumatology Reviews A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug
Current Molecular Pharmacology Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics
Current Clinical Pharmacology Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors
Current Molecular Medicine Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Neuroinflammation in Sepsis: Sepsis Associated Delirium
Cardiovascular & Hematological Disorders-Drug Targets Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design